Overview

Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients

Status:
ENROLLING_BY_INVITATION
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
This study is to assess the efficacy and safety of venetoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Treatments:
venetoclax